PBMCs microRNA-122 level correlates with virological responses to pegylated interferon alpha therapy in patients with hepatitis C genotype 1b
10.3760/cma.j.issn.1003-9279.2017.06.015
- VernacularTitle: 基因1型慢性丙型肝炎血清MicroRNA-122的表达与干扰素应答的相关性研究
- Author:
Jianping LI
1
;
Nenglang PAN
;
Zhiwei XIE
;
Keli YANG
;
Yujuan GUAN
;
Xiaoping TANG
Author Information
1. Department of Liver Disease, Guangzhou Eighth People′s Hospital, Guangzhou 510060, China
- Publication Type:Journal Article
- Keywords:
MiR-122;
Hepatitis C;
Pegylated interferon alpha;
Ribavirin
- From:
Chinese Journal of Experimental and Clinical Virology
2017;31(6):549-553
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To clarify the predictive power of PBMCs miR-122, as well as other clinical factors, for response to IFNα therapy in chronic HCV infected patients.
Methods:A total of 40 patients chronically infected with HCV genotype 1b were enrolled. All the patients received pegylated interferon alpha (PEG-IFN α) in combination with ribavirin for 48 weeks. To perform the analyses, the patients were compared in terms of achieving sustained virological response (SVR) or not (NSVR) at 24th week after antiviral treatment.
Results:SVR rate was 72.5% (29/40) and NSVR rate was 27.5% (11/40). SVR group experienced significantly lower HCV viral load, total bilirubin (TBIL), alpha fetal protein (AFP), fibroscan and laminin (LN) compared with NSVR group before treatment (P<0.05). PBMCs miR-122 expression level was also lower in SVR group than that in SNVR group, although the difference was not statistically significant (P>0.05). and there was no significant change of miR-122 level from baseline to the last available measurement between SVR group and NSVR group. However, no significant association was found between baseline PBMCs miR-122 and HCV viral load, body mass index (BMI), alanine transaminase (ALT), aspartate transaminase (AST), degree of liver fibrosis, respectively.
Conclusions:Our result suggest that PBMCs miR-122 level is not an efficient biomarker to predict response to IFN alpha therapy in chronic HCV patients. However, baseline HCV viral load, TBIL, AFP and fibroscan may serve as predictive factors.
